Priority Review for Dersimelagon in the Treatment of EPP and XLP @checkrare
Priority Review for Dersimelagon in the Treatment of EPP and XLP  @checkrare
Uploaded October 2026 | Updated November 2026, 4 days ago
Lukasz Jarzyna, Vice President of Rare Disease at LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).

EPP and XLP are rare congenital metabolic disorders characterized by an inborn error of porphyrin-heme biosynthesis. Signs and symptoms include painful cutaneous photosensitivity that results in tingling, burning, pain, and itching within minutes of sun/light exposure and may be accompanied by swelling and redness. Other symptoms may include erythrodontia, red discoloration of urine, hemolytic anemia, and splenomegaly.

On September 18, the US Food and Drug Administration (FDA) announced Priority Review to the New Drug Application (NDA) for dersimelagon for the treatment of EPP and XLP, with a PDUFA date of February 2027. Dersimelagon is an investigational, once-daily oral small-molecule MC1R agonist being developed for EPP and XLP. Under a Priority Review designation, the FDA aims to take action on an application within 6 months, compared to 10 months under standard review. LEO Pharma also announced an acquisition of worldwide rights to dersimelagon from Tanabe Pharma.

Earlier this year, Tanabe Pharma announced results from the global, randomized, double-blind, placebo-controlled phase 3 INSPIRE clinical trial (NCT06144840). Dersimelagon demonstrated statistically significant and clinically meaningful outcomes across primary and secondary endpoints, including a significant prolongation of average daily sunlight exposure time to first prodromal symptoms.

If approved, dersimelagon could become the first oral treatment for EPP and XLP. Dersimelagon has not yet been approved by the FDA or any other regulatory authority, and its safety and efficacy have not been established by any regulatory authority.

For more information, visit leo-pharma.com/media-center/news/leo-pharma-announces-fda-acceptance-of-dersimelagon-nda-with-priority-review-and-closes-acquisition-from-tanabe-pharma

To learn more about EPP and XLP and other rare skin conditions, visit checkrare.com/diseases/skin-conditions

Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.

Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.

Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.

Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Priority Review for Dersimelagon in the Treatment of EPP and XLPPlasma Proteomics May Predict Disease Manifestations in ALSUltragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare BriefPrimary Versus Severe IGF-1 DeficiencyHighlights from The Liver Meeting 2026Fabry Disease: How Well Does Your Medical Team Work Together and Understand Fabry Disease?Increased Dosing Interval of Mogamulizumab in Patients With CTCLThe Changing Myasthenia Gravis Treatment LandscapePatient Perspective: Diagnostic Journey With IgA NephropathyC3G and the Pediatric VALIANT StudyIMAAVY Approval for wAIHAFDA Approves Multiple Myeloma Drug;  FDA Denies Neuroendocrine Drug; Safety Concerns For Prader-W...
CheckRare |

Priority Review for Dersimelagon in the Treatment of EPP and XLP

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER